https://www.selleckchem.com/products/medica16.html
Patients with -mutant and wild-type melanoma have different response rates to immune checkpoint blockade therapy. However, the reasons for this remain unknown. To address this issue, we investigated the precise immune composition resulting from mutation in treatment-naive melanoma to determine whether this may be a driver for different response to immunotherapy. In this study, we characterized the treatment-naive immune context in patients with -mutant and wild-type ( -wt) melanoma using data from single-cell RNA sequencing, bulk RNA s
Like
Comment
Share
